[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1503
21. Svojgr K, Burjanivova T, Vaskova M, Kalina T, Stary J, Trka J, Zuna J: Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia. Immunol Lett; 2009 Feb 21;122(2):185-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adaptor molecules expression in normal lymphopoiesis and in childhood leukemia.
  • By influencing proliferation and differentiation, these molecules might play a role in ethiopathogenesis of acute lymphoblastic leukemia (ALL).
  • Moreover, diagnostic samples of childhood ALL cases were analyzed.
  • During normal lymphocyte development, some adaptors show significant dynamics (gradual decrease of NTAL and increase of LAT and LIME during the T-cell maturation, decrease of PAG in B-precursors, high levels of LIME in peripheral B-lymphocytes).
  • Analysis of childhood ALL samples revealed that in B-cell precursor ALL, the TEL/AML1 subgroup have unique adaptor profile compared to other leukemias.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. B-Lymphocytes / metabolism. Lymphopoiesis / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. T-Lymphocytes / metabolism
  • [MeSH-minor] Adaptor Proteins, Vesicular Transport / immunology. Biomarkers, Tumor. Cell Differentiation / immunology. Cell Lineage. Cell Proliferation. Child. Humans. Membrane Proteins / genetics. Membrane Proteins / immunology. Membrane Proteins / metabolism. Signal Transduction / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19183565.001).
  • [ISSN] 1879-0542
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adaptor Proteins, Vesicular Transport; 0 / Biomarkers, Tumor; 0 / LAT protein, human; 0 / LAT2 protein, human; 0 / Lck-interacting protein, human; 0 / Membrane Proteins; 0 / PAG1 protein, human
  •  go-up   go-down


22. Dorak MT, McNally RJ, Parker L: Re: "Childhood acute lymphoblastic leukemia and infections in the first year of life: a report from the United Kingdom childhood cancer study". Am J Epidemiol; 2007 Aug 1;166(3):364-5; author reply 365
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: "Childhood acute lymphoblastic leukemia and infections in the first year of life: a report from the United Kingdom childhood cancer study".
  • [MeSH-major] HLA-DP Antigens / genetics. Infection / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


23. Sprehe MR, Barahmani N, Cao Y, Wang T, Forman MR, Bondy M, Okcu MF: Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors. Pediatr Blood Cancer; 2010 Feb;54(2):242-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors.
  • INTRODUCTION: High birth weight (HBW) is an established risk factor for childhood acute lymphoblastic leukemia (ALL).
  • BW was not an independent risk factor for acute myeloid leukemia or brain tumors.

  • MedlinePlus Health Information. consumer health - Birth Weight.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Am J Pathol. 1994 Oct;145(4):802-17 [7943172.001]
  • [Cites] Pediatr Endocrinol Rev. 2009 Feb;6 Suppl 3:332-6 [19404231.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 21;87(12):908-14 [7666480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):441-5 [7549797.001]
  • [Cites] Cancer Causes Control. 1996 Sep;7(5):553-9 [8877054.001]
  • [Cites] Ann Epidemiol. 1997 Apr;7(3):172-9 [9141639.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] J Pediatr. 1997 Nov;131(5):671-7 [9403644.001]
  • [Cites] Am J Perinatol. 1998 Jan;15(1):23-8 [9475683.001]
  • [Cites] J Pediatr. 1999 Feb;134(2):138-40 [9931517.001]
  • [Cites] Matern Child Health J. 2009 Sep;13(5):660-6 [18766434.001]
  • [Cites] Pediatr Int. 2000 Feb;42(1):31-6 [10703231.001]
  • [Cites] J Pediatr Endocrinol Metab. 2000 Mar;13(3):289-96 [10714754.001]
  • [Cites] Matern Child Health J. 1999 Dec;3(4):225-31 [10791363.001]
  • [Cites] Obstet Gynecol. 2000 Nov;96(5 Pt 1):707-13 [11042305.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):935-8 [11158070.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 1999 Mar;34(3):135-7 [11263179.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2001 Apr 25;81(8):489-92 [11798925.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):603-13 [11914187.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1078-80 [11953852.001]
  • [Cites] Obstet Gynecol. 2002 Sep;100(3):567-73 [12220780.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):595-602 [12296506.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):922-4; discussion 925 [15128602.001]
  • [Cites] Pediatr Res. 1973 Mar;7(3):132-8 [4511339.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] J Natl Cancer Inst. 1984 May;72(5):1039-41 [6585581.001]
  • [Cites] Pediatr Hematol Oncol. 1994 Nov-Dec;11(6):587-99 [7857782.001]
  • [Cites] Int J Epidemiol. 1999 Aug;28(4):631-9 [10480689.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):125-34 [16021070.001]
  • [Cites] Cancer Causes Control. 2007 Aug;18(6):655-63 [17503007.001]
  • [Cites] Am J Epidemiol. 2007 Jul 15;166(2):151-9 [17443021.001]
  • [Cites] Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12 [17569110.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2658-70 [19173295.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):63-72 [3152913.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3696-701 [2065325.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1351-5 [1873786.001]
  • [Cites] Am J Epidemiol. 1984 May;119(5):788-95 [6720675.001]
  • (PMID = 19813253.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA057730-13; United States / NCI NIH HHS / CA / R25 CA057730; United States / NCI NIH HHS / CA / R25 CA057730-13; United States / NCI NIH HHS / CA / R25 CA57730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS144377; NLM/ PMC2795053
  •  go-up   go-down


2
Advertisement
4. Snyder DS, Stein AS, O'Donnell MR, Gaal K, Slovak ML, Forman SJ: Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature. Am J Hematol; 2005 Jan;78(1):74-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature.
  • Survivors of childhood solid tumors including Ewing sarcoma (ES) have an increased risk of secondary malignant neoplasms (SMNs) as a consequence of exposure to chemotherapy and/or radiation (see: Bhatia S, Sklar C.
  • The most common hematologic SMNs are myelodysplasia (MDS) and acute myelogenous leukemia (AML).
  • Acute lymphoblastic leukemia (ALL) is uncommon in this patient population, and Philadelphia chromosome positive (Ph+) ALL in particular, is rare.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Radiation Injuries / complications. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / radiotherapy


25. Crom DB, Tyc VL, Rai SN, Deng X, Hudson MM, Booth A, Rodrigues LN, Zhang L, McCammon E, Kaste SC: Retention of survivors of acute lymphoblastic leukemia in a longitudinal study of bone mineral density. J Child Health Care; 2006 Dec;10(4):337-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retention of survivors of acute lymphoblastic leukemia in a longitudinal study of bone mineral density.
  • Attrition in longitudinal studies of survivors of childhood cancer reduces these studies' statistical power, introduces bias and threatens internal and external validity.
  • This study investigated the variables associated with dropout of survivors of acute lymphoblastic leukemia in a trial investigating the effect of vitamin D and calcium supplementation and nutritional counseling on bone mineral density (BMD).
  • [MeSH-major] Attitude to Health. Longitudinal Studies. Motivation. Patient Dropouts / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Survivors / psychology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101625.001).
  • [ISSN] 1367-4935
  • [Journal-full-title] Journal of child health care : for professionals working with children in the hospital and community
  • [ISO-abbreviation] J Child Health Care
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


96. Tissing WJ, Meijerink JP, den Boer ML, Brinkhof B, van Rossum EF, van Wering ER, Koper JW, Sonneveld P, Pieters R: Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia. Clin Cancer Res; 2005 Aug 15;11(16):6050-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia.
  • Glucocorticoid sensitivity is an important prognostic factor in pediatric acute lymphoblastic leukemia (ALL).
  • Our data suggest that these genetic variations are not a major contributor for differences in cellular response to glucocorticoids in childhood ALL.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Genetic Variation. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Glucocorticoid / genetics
  • [MeSH-minor] Base Sequence. Cell Survival / drug effects. Cell Survival / genetics. Child. Child, Preschool. DNA Mutational Analysis. DNA, Neoplasm / chemistry. DNA, Neoplasm / genetics. Female. Genotype. Humans. Infant. Infant, Newborn. Male. Mutation. Polymorphism, Genetic. Polymorphism, Single-Stranded Conformational. Prednisolone / pharmacology. Tumor Cells, Cultured


97. Jones OY, Spencer CH, Bowyer SL, Dent PB, Gottlieb BS, Rabinovich CE: A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. Pediatrics; 2006 May;117(5):e840-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis.
  • OBJECTIVE: Acute lymphocytic leukemia (ALL) often presents with musculoskeletal concerns such as pain or swelling, even before appearance of blasts in the peripheral blood.
  • This study was designed to identify the predictive factors for leukemia using basic clinical and laboratory information.
  • METHODS: A retrospective chart review was performed using a simple questionnaire to compare the clinical and laboratory findings present during the initial visit to a pediatric rheumatology clinic for 277 children who were ultimately diagnosed with either JRA (n = 206) or ALL (n = 71).
  • RESULTS: The majority (75%) of children with ALL did not have blasts in the peripheral blood at the time of evaluation by pediatric rheumatologists.
  • In children presenting with unexplained musculoskeletal complaints, the 3 most important factors that predicted a diagnosis of ALL were low white blood cell count (< 4 x 10(9)/L), low-normal platelet count (150-250 x 10(9)/L), and history of nighttime pain.
  • CONCLUSIONS: When a child develops new-onset bone-joint complaints, the presence of subtle complete blood count changes combined with nighttime pain should lead to consideration of leukemia as the underlying cause.
  • [MeSH-major] Arthritis, Juvenile / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis


98. Moyer-Mileur LJ, Ransdell L, Bruggers CS: Fitness of children with standard-risk acute lymphoblastic leukemia during maintenance therapy: response to a home-based exercise and nutrition program. J Pediatr Hematol Oncol; 2009 Apr;31(4):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fitness of children with standard-risk acute lymphoblastic leukemia during maintenance therapy: response to a home-based exercise and nutrition program.
  • BACKGROUND: Altered nutrient intake and decreased exercise in response to cancer therapies and their side effects, particularly corticosteroids, may be key factors in the increased body weight and differences in physical fitness reported in survivors of childhood acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child Nutritional Physiological Phenomena. Exercise. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diet therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


99. Yang CP, Hung IJ, Jaing TH, Shih LY, Chang WH: Cancer in infants: a review of 82 cases. Pediatr Hematol Oncol; 2005 Sep;22(6):463-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute leukemia was diagnosed in 21 infants (25.6%; acute myeloid leukemia in 12, and acute lymphoblastic leukemia in 9), retinoblastoma in 14 (17.1%), neuroblastoma in 12 (14.6%), brain tumor in 9 (11.0%), germ cell tumor in 8 (9.8%), renal cancer in 8 (Wilms tumor 3, mesoblastic nephroma 1, renal sarcoma 1, rhabdoid tumor 3), hepatoblastoma in 5 (6.1%), and soft tissue sarcoma in 5 (rhabdomyosarcoma 1, fibrosarcoma 3, other sarcoma 1).
  • The 4 most common types of cancer occurring in infants are the same in the present series and in most larger childhood cancer series reported by other countries; but rank differently.
  • In this study there were more infants with acute leukemia and retinoblastoma, and less with neuroblastoma.
  • The prognosis is poor for infant leukemia and rhabdoid tumor, while it is good for embryonal tumors and germ cell tumors occurring in infancy.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169813.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


100. Yamaji K, Okamoto T, Yokota S, Watanabe A, Horikoshi Y, Asami K, Kikuta A, Hyakuna N, Saikawa Y, Ueyama J, Watanabe T, Okada M, Taga T, Kanegane H, Kogawa K, Chin M, Iwai A, Matsushita T, Shimomura Y, Hori T, Tsurusawa M, Japanese Childhood Cancer Leukemia Study Group: Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer; 2010 Dec 15;55(7):1287-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
  • BACKGROUND: The majority of minimal residual disease (MRD)-positive patients with acute lymphoblastic leukemia (ALL) have poor outcomes.
  • The ALL2000 study was performed to evaluate the efficacy of augmented chemotherapy based on MRD-restratification in childhood ALL.
  • PROCEDURE: Between 2000 and 2004, 305 eligible patients with precursor B or T-cell ALL were enrolled in the ALL2000 study.
  • The ALL941-based therapy protocol utilized PCR MRD assays using Immunoglobulin and T-cell receptor gene rearrangements.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy






Advertisement